Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biovelop was a Swedish biotechnology company specializing in the fractionation of oats to produce high-value ingredients for the food, beverage, and cosmetics industries. The company developed a proprietary, chemical-free technology to extract oat beta-glucan, which was marketed under the brand name Avenacare. These ingredients are widely used in skincare for their soothing and anti-aging properties, as well as in food products for their heart health benefits. In 2013, Biovelop was acquired by Tate & Lyle, a global leader in specialty food ingredients. The acquisition allowed Tate & Lyle to enhance its health and wellness portfolio with sustainable, plant-based solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biovelop.